Intech Investment Management LLC Has $1.18 Million Position in Inari Medical, Inc. (NASDAQ:NARI)

Intech Investment Management LLC raised its stake in shares of Inari Medical, Inc. (NASDAQ:NARI) by 33.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,159 shares of the company’s stock after buying an additional 5,794 shares during the quarter. Intech Investment Management LLC’s holdings in Inari Medical were worth $1,182,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. KBC Group NV lifted its stake in Inari Medical by 39.0% in the 3rd quarter. KBC Group NV now owns 1,774 shares of the company’s stock valued at $73,000 after acquiring an additional 498 shares in the last quarter. Quest Partners LLC lifted its stake in Inari Medical by 84.6% in the 3rd quarter. Quest Partners LLC now owns 4,051 shares of the company’s stock valued at $167,000 after acquiring an additional 1,856 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Inari Medical by 11.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 84,968 shares of the company’s stock valued at $3,504,000 after acquiring an additional 8,465 shares in the last quarter. Landscape Capital Management L.L.C. bought a new stake in Inari Medical in the 3rd quarter valued at approximately $291,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in Inari Medical by 0.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 453,972 shares of the company’s stock valued at $18,722,000 after acquiring an additional 1,783 shares in the last quarter. 90.98% of the stock is currently owned by institutional investors and hedge funds.

Inari Medical Price Performance

Shares of NASDAQ NARI opened at $79.97 on Friday. The stock’s fifty day moving average price is $79.81 and its two-hundred day moving average price is $60.18. Inari Medical, Inc. has a one year low of $36.73 and a one year high of $79.99. The firm has a market cap of $4.68 billion, a price-to-earnings ratio of -59.24 and a beta of 1.02.

Insider Buying and Selling at Inari Medical

In other Inari Medical news, Director William Hoffman sold 200,000 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $60.47, for a total value of $12,094,000.00. Following the transaction, the director now directly owns 238,987 shares of the company’s stock, valued at $14,451,543.89. This represents a 45.56 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 10.60% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on NARI. BTIG Research reiterated a “neutral” rating on shares of Inari Medical in a research note on Wednesday, January 8th. Piper Sandler upped their price objective on Inari Medical from $52.00 to $80.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 7th. Robert W. Baird reiterated a “neutral” rating and set a $80.00 price objective (down previously from $81.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Truist Financial upped their price objective on Inari Medical from $50.00 to $63.00 and gave the stock a “hold” rating in a research note on Wednesday, December 18th. Finally, Canaccord Genuity Group reiterated a “hold” rating and set a $80.00 price objective (up previously from $74.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Twelve research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $68.00.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.